Optimal  ||| S:0 E:8 ||| JJ
duration  ||| S:8 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
SLIT  ||| S:20 E:25 ||| NNP
A  ||| S:25 E:27 ||| DT
review  ||| S:27 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
SLIT  ||| S:37 E:42 ||| NNP
studies  ||| S:42 E:50 ||| NNS
reveals  ||| S:50 E:58 ||| VBZ
that  ||| S:58 E:63 ||| IN
both  ||| S:63 E:68 ||| DT
cumulative  ||| S:68 E:79 ||| JJ
dose  ||| S:79 E:84 ||| NN
and  ||| S:84 E:88 ||| CC
maintenance  ||| S:88 E:100 ||| NN
schedules  ||| S:100 E:110 ||| NNS
have  ||| S:110 E:115 ||| VBP
widely  ||| S:115 E:122 ||| RB
varied  ||| S:122 E:129 ||| VBN
between  ||| S:129 E:137 ||| IN
the  ||| S:137 E:141 ||| DT
published  ||| S:141 E:151 ||| VBN
clinical  ||| S:151 E:160 ||| JJ
trials ||| S:160 E:166 ||| NNS
.  ||| S:166 E:168 ||| .
Pre-co-seasonal  ||| S:168 E:184 ||| JJ
treatment  ||| S:184 E:194 ||| NN
for  ||| S:194 E:198 ||| IN
pollen  ||| S:198 E:205 ||| JJ
allergy  ||| S:205 E:213 ||| NN
seems  ||| S:213 E:219 ||| VBZ
to  ||| S:219 E:222 ||| TO
be  ||| S:222 E:225 ||| VB
better  ||| S:225 E:232 ||| JJR
than  ||| S:232 E:237 ||| IN
coseasonal  ||| S:237 E:248 ||| JJ
treatment ||| S:248 E:257 ||| NN
.  ||| S:257 E:259 ||| .
There  ||| S:259 E:265 ||| EX
is  ||| S:265 E:268 ||| VBZ
a  ||| S:268 E:270 ||| DT
number  ||| S:270 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
studies  ||| S:280 E:288 ||| NNS
evaluating  ||| S:288 E:299 ||| VBG
different  ||| S:299 E:309 ||| JJ
durations  ||| S:309 E:319 ||| NN
of  ||| S:319 E:322 ||| IN
SLIT ||| S:322 E:326 ||| NNP
,  ||| S:326 E:328 ||| ,
but  ||| S:328 E:332 ||| CC
the  ||| S:332 E:336 ||| DT
heterogeneity  ||| S:336 E:350 ||| NN
of  ||| S:350 E:353 ||| IN
the  ||| S:353 E:357 ||| DT
study  ||| S:357 E:363 ||| NN
design ||| S:363 E:369 ||| NN
,  ||| S:369 E:371 ||| ,
allergen  ||| S:371 E:380 ||| JJ
extracts  ||| S:380 E:389 ||| NN
and  ||| S:389 E:393 ||| CC
outcome  ||| S:393 E:401 ||| NN
measures  ||| S:401 E:410 ||| NNS
make  ||| S:410 E:415 ||| VBP
it  ||| S:415 E:418 ||| PRP
difficult  ||| S:418 E:428 ||| JJ
to  ||| S:428 E:431 ||| TO
produce  ||| S:431 E:439 ||| VB
a  ||| S:439 E:441 ||| DT
meta-analysis  ||| S:441 E:455 ||| JJ
on  ||| S:455 E:458 ||| IN
SLIT  ||| S:458 E:463 ||| NNP
efficacy  ||| S:463 E:472 ||| VBZ
according  ||| S:472 E:482 ||| VBG
to  ||| S:482 E:485 ||| TO
duration ||| S:485 E:493 ||| VB
.  ||| S:493 E:495 ||| .
Overall ||| S:495 E:502 ||| RB
, ||| S:502 E:503 ||| ,
duration  ||| S:503 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
both  ||| S:515 E:520 ||| PDT
the  ||| S:520 E:524 ||| DT
build-up  ||| S:524 E:533 ||| NN
phase  ||| S:533 E:539 ||| NN
and  ||| S:539 E:543 ||| CC
the  ||| S:543 E:547 ||| DT
maintenance  ||| S:547 E:559 ||| NN
treatment  ||| S:559 E:569 ||| NN
does  ||| S:569 E:574 ||| VBZ
not  ||| S:574 E:578 ||| RB
seem  ||| S:578 E:583 ||| VB
to  ||| S:583 E:586 ||| TO
influence  ||| S:586 E:596 ||| VB
the  ||| S:596 E:600 ||| DT
effectiveness  ||| S:600 E:614 ||| NN
of  ||| S:614 E:617 ||| IN
SLIT ||| S:617 E:621 ||| NNP
.  ||| S:621 E:623 ||| .
This  ||| S:623 E:628 ||| DT
suggests  ||| S:628 E:637 ||| VBZ
that  ||| S:637 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
quality  ||| S:646 E:654 ||| NN
of  ||| S:654 E:657 ||| IN
the  ||| S:657 E:661 ||| DT
extract  ||| S:661 E:669 ||| NN
is  ||| S:669 E:672 ||| VBZ
more  ||| S:672 E:677 ||| RBR
important  ||| S:677 E:687 ||| JJ
in  ||| S:687 E:690 ||| IN
determining  ||| S:690 E:702 ||| VBG
the  ||| S:702 E:706 ||| DT
clinical  ||| S:706 E:715 ||| JJ
response  ||| S:715 E:724 ||| NN
to  ||| S:724 E:727 ||| TO
SLIT  ||| S:727 E:732 ||| NNP
than  ||| S:732 E:737 ||| IN
duration  ||| S:737 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
therapy ||| S:749 E:756 ||| NN
.  ||| S:756 E:758 ||| .
Further  ||| S:758 E:766 ||| JJ
studies  ||| S:766 E:774 ||| NNS
are  ||| S:774 E:778 ||| VBP
warranted  ||| S:778 E:788 ||| VBN
to  ||| S:788 E:791 ||| TO
establish  ||| S:791 E:801 ||| VB
optimal  ||| S:801 E:809 ||| JJ
duration  ||| S:809 E:818 ||| NN
of  ||| S:818 E:821 ||| IN
SLIT  ||| S:821 E:826 ||| NNP
treatment ||| S:826 E:835 ||| NN
.  ||| S:835 E:837 ||| .
